Hospital Universitario de La Princesa

BioFRAM PGx, an Implementation Proposal for Pharmacogenetics in the Spanish National Health System

Background/Objectives: Pharmacogenetics (PGx) may improve drug safety and effectiveness, but its integration into routine care remains heterogeneous across the Spanish National Health System (NHS). This article presents BioFRAM PGx, a multicentre implementation framework that def...

Sex differences in epidemiology and clinical presentation of glomerular diseases in a nationwide Spanish biopsy registry

Sex differences influence the epidemiology and clinical expression of kidney diseases. Most primary glomerulonephritis shows male predominance, whereas lupus nephritis remains strongly female-biased. Large national cohorts with sex-stratified analyses are limited. We analysed all...

Working conditions and mental health among doctors and nurses in the European Union, Iceland, and Norway: a cross-sectional survey

Background Europe faces persistent challenges in retaining and recruiting healthcare workers. Poor working conditions and deteriorating wellbeing may contribute to attrition and turnover intentions, yet large-scale studies examining associations between working conditions and men...

Variability in the Application and Principles of Prehabilitation and Enhanced Recovery (VAPPER Survey) Among Colorectal Surgery Units: A National Multicentre Survey

Background: Prehabilitation has become an essential component of perioperative care in colorectal surgery, aiming to improve postoperative outcomes through multimodal interventions. However, its real-world implementation remains heterogeneous. This study aimed to evaluate the deg...

Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group

Treatment-free remission (TFR) is an established therapeutic goal for patients with chronic myeloid leukemia (CML) achieving sustained deep molecular response (DMR) on tyrosine kinase inhibitors (TKIs). However, evidence on TFR following bosutinib discontinuation remains limited....